Skip to search formSkip to main contentSkip to account menu

pimavanserin

Known as: N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide 
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (2)

ACP 103Nuplazid

Broader (5)

Antiparkinson AgentsAntipsychotic AgentsPiperidinesSerotonin 5-HT2 Receptor Agonists
Schizophrenia Spectrum and Other Psychotic Disordersanalogs & derivativespimavanserin 17 MG Oral Tablet [Nuplazid]pimavanserin tartrate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
The aim of this editorial is to evaluate the evidence for using pimavanserin for the treatment of Parkinson's disease psychosis… 
Review
2017
Review
2017
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study
Parkinson's disease psychosis (PDP) is a frequent complication of idiopathic Parkinson's disease (iPD) with significant impact on… 
Review
2017
Review
2017
A Retrospective Study of Pimavanserin Use in a Movement Disorders Clinic
Abstract Pimavanserin, a 5-HT2A inverse agonist, was commercially released in the United States in April 2016 for the treatment… 
Review
2017
Review
2017
Pimavanserin, a novel antipsychotic for management of Parkinson’s disease psychosis
ABSTRACT Introduction: Parkinson’s disease psychosis (PDP) may develop in up to 60% of Parkinson’s patients and is associated… 
2016
2016
Pimavanserin: An Inverse Agonist Antipsychotic Drug.
Approximately all clinically useful antipsychotic drugs have known activity as dopamine receptor antagonists, but many of these… 
2013
2013
Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
No safe, tolerated, and effective treatment for Parkinson's disease psychosis (PDP) is available; however, clozapine and… 
2012
2012
Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a progressive deterioration in cognitive functioning… 
2012
2012
Prevention of the Phencyclidine-Induced Impairment in Novel Object Recognition in Female Rats by Co-Administration of Lurasidone or Tandospirone, a 5-HT1A Partial Agonist
Hypoglutamatergic function may contribute to cognitive impairment in schizophrenia (CIS). Subchronic treatment with the N-methyl… 
Review
2010
Review
2010
Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects.
Benzodiazepine (BZD) and non-BZD hypnotics improve sleep induction and sleep maintenance. BZD induces a further reduction of slow… 
Highly Cited
2008
Highly Cited
2008
5-HT(2A) inverse-agonists for the treatment of insomnia.
Nearly one half of the adult population in the U.S. experience some symptoms of insomnia (difficulties with getting to sleep… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)